Date published: 2025-11-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

GalNAc-T3 Inhibitors

GalNAc-T3, also known as polypeptide N-acetylgalactosaminyltransferase 3, is an enzyme that plays a crucial role in the process of glycosylation, where it catalyzes the addition of N-acetylgalactosamine to serine and threonine residues on proteins. This modification is fundamental in the molecular architecture of glycoproteins and is essential for the stability and function of many protein complexes. The expression of GalNAc-T3 is tightly controlled within cells, as it is integral to numerous biological processes, including cell signaling, protein interactions, and cellular responses to external stimuli. Given its significance in these pathways, the aberrant expression of GalNAc-T3 can lead to alterations in cellular functions and homeostasis. Consequently, understanding the regulation of this enzyme is of substantial interest within the field of molecular biology. Inhibiting the expression of GalNAc-T3, whether for experimental purposes or as part of a broader investigation into the modulation of glycosylation pathways, can be approached using various chemical inhibitors. These inhibitors can operate through multiple mechanisms, such as affecting the transcriptional machinery directly at the gene level or by altering epigenetic markers, which in turn can lead to downregulation of gene expression. For example, certain compounds can be incorporated into the genome and interfere with the normal methylation patterns, leading to changes in the chromatin structure that render the GalNAc-T3 gene less accessible for transcription. Other chemicals may inhibit specific enzymes responsible for post-translational modifications of histones, thereby decreasing the transcriptional activity of genes like GalNAc-T3. Additionally, the interruption of signal transduction pathways that convey growth factor or hormone signals to the transcriptional apparatus can also result in the diminished expression of GalNAc-T3. The precise action of these inhibitors often depends on their chemical structure and the specific intracellular targets they engage with, making the exploration of these substances a complex and nuanced field of study.

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

This cytidine analogue may cause DNA demethylation at the GalNAc-T3 gene locus, leading to transcriptional repression of this gene.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$149.00
$470.00
$620.00
$1199.00
$2090.00
33
(3)

By inhibiting histone deacetylase activity, Trichostatin A can result in hyperacetylation of histones, which can downregulate GalNAc-T3 expression by altering chromatin structure.

RG 108

48208-26-0sc-204235
sc-204235A
10 mg
50 mg
$128.00
$505.00
2
(1)

RG 108 could hinder the methylation of the GalNAc-T3 gene promoter, thereby decreasing its transcriptional activity and subsequent protein expression.

5-Aza-2′-Deoxycytidine

2353-33-5sc-202424
sc-202424A
sc-202424B
25 mg
100 mg
250 mg
$214.00
$316.00
$418.00
7
(1)

As a nucleoside analogue, 5-Aza-2′-Deoxycytidine (Decitabine) can incorporate into DNA and reduce methylation levels, leading to a decrease in GalNAc-T3 expression through altered gene silencing.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$130.00
$270.00
37
(2)

Suberoylanilide Hydroxamic Acid's ability to inhibit histone deacetylases may result in a chromatin state that is less permissive for the transcription of the GalNAc-T3 gene, thereby reducing its expression.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Although primarily an mTOR inhibitor, Rapamycin (Sirolimus) could decrease GalNAc-T3 expression by hindering downstream protein synthesis signaling that might otherwise upregulate this glycosyltransferase.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

By inhibiting phosphoinositide 3-kinases, LY 294002 can lead to a reduction in the transcriptional activity of genes downstream of this pathway, potentially including GalNAc-T3.

Wnt-C59

1243243-89-1sc-475634
sc-475634A
sc-475634B
5 mg
10 mg
50 mg
$210.00
$320.00
$1250.00
1
(0)

Wnt-C59 inhibits the production of Wnt proteins, which could lead to a decrease in the transcriptional activity of GalNAc-T3 if it is under the control of Wnt-responsive elements.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

By specifically inhibiting MEK, which is upstream of ERK in the MAPK pathway, PD 98059 could disrupt signals necessary for maintaining GalNAc-T3 expression.

Histone Lysine Methyltransferase Inhibitor Inhibitor

935693-62-2 free basesc-202651
5 mg
$148.00
4
(1)

This inhibitor targets the histone methyltransferase G9a, potentially leading to reduced histone methylation and a decrease in the expression of genes like GalNAc-T3.